Claims for Patent: 8,334,265

Summary for Patent: 8,334,265

Title:	Method of treatment of photodermatoses
Abstract:	This invention relates to a method for prophylactic or therapeutic treatment of photodermatoses that are caused or exacerbated by or associated with UVR exposure in a subject, particularly a human subject, which comprises the step of administering to said subject an amount of an alpha-MSH analogue effective to reduce the photosensitivity of the skin of the subject.
Inventor(s):	Wolgen; Philippe (Melbourne, AU)
Assignee:	Clinuvel Pharmaceuticals Limited (Melbourne, Victoria, AU)
Application Number:	12/438,990
Patent Claims:	1. A method for treating a human subject suffering from photodermatoses that are caused or exacerbated by or associated with ultraviolet radiation (UVR) exposure which comprises the step of administering to said subject an amount of [Nle.sup.4, D-Phe.sup.7]-alpha-melanocyte stimulating hormone (alpha-MSH) effective to reduce the photosensitivity of the skin of the subject. 2. The method of claim 1, wherein the photodermatosis is erythropoietic photoporphyria (EPP). 3. The method of claim 1, wherein the photodermatosis is solar urticaria (SU). 4. The method of claim 1, wherein the photodermatosis is polymorphous light eruption (PLE).